Many companies across sectors ranging from biotech to real estate investment trusts kicked off initial public offerings on Monday as issuers gear up to move forward with their IPO plans amidst the Middle East conflict.
Analysts believe that conditions are ripe for a gradual recovery in activity in the coming months if the volatility subsides.
C-store owner Yesway, proteomic company Alamar Biosciences, obesity drug developer Kailera Therapeutics, and real estate investment firm National Healthcare Properties unveiled the terms of their respective offerings on Monday.
“This reflects the number of companies waiting for an IPO that are on the sidelines. A number of issuers just need to see a sign of stability and they will launch their offerings,” said Matt Kennedy, senior strategist at Renaissance Capital, a provider of IPO-focused research and ETFs.
The VIX volatility index, Wall Street’s fear gauge, dropped below 20 last week for the first time in over a month.
A value below 20 could signal greater stability in the markets.
HOPE OF AN IPO REBOUND REMAINS INTACT
The IPO market struggled to gain momentum in February and March as market volatility episodes related to AI disruption fears and the Middle East conflict kept issuers on the sidelines.
But “2026 is still on track to be the best year for IPOs since the post-pandemic drought, and it could even achieve that without mega-listings,” said Lukas Muehlbauer, IPOX research associate.
<p"The pricing discipline and attractive valuations make this year a buyer's market, giving these deals better chances of trading well post-IPO."
From defense to REIT sectors, six companies made their IPO requests public on Friday, bolstering the short-term pipeline.
However, some uncertainty lingers after weekend talks between the U.S. and Iran failed to reach an agreement to end the war.
Bill Ackman’s Pershing Square also kicked off a roadshow for IPOs in the U.S. by the billionaire investor’s management firm and a new fund.
